Latest News

• Biocon Limited's Fund Raising Committee, at its meeting held on Monday, June 16, 2025, authorized the opening of its Qualified Institutions Placement (QIP) for equity shares.
• This QIP follows approvals from the Board of Directors on April 23, 2025, and shareholders via postal ballot on June 04, 2025.
• The committee approved the floor price for the Issue at ₹ 340.20 per Equity Share, determined as per SEBI ICDR Regulations.
• The company reserves the discretion to offer a discount of not more than 5% on the stated floor price.
• The final Issue price will be determined in consultation with the appointed Book Running Lead Managers.
• The preliminary placement document dated June 16, 2025, along with the application form, has been approved and adopted.
• The trading window for dealing in the company's securities has been closed until further notice for the purpose of this Issue.

• Biocon Limited's Board of Directors approved the audited consolidated financial statements for the year ended March 31, 2025, on May 08, 2025.
• The financial statements were prepared in accordance with the Companies Act, 2013 and Indian Accounting Standards (Ind-AS).
• The audited consolidated financial statements are subject to approval by shareholders at the Annual General Meeting scheduled for August 08, 2025.
• B S R & Co. LLP, Chartered Accountants, have issued an independent auditor's report, providing an opinion that the consolidated financial statements give a true and fair view of the Group's consolidated state of affairs as of March 31, 2025.

Biocon Foundation, the Corporate Social Responsibility arm of Biocon Group, in collaboration with The Bengaluru Science and Technology (BeST) Cluster and National Centre for Biological Sciences (NCBS), announced the launch of the BioWISE - Women in STEM Empowered program on June 9, 2025.

• The program is designed to empower disadvantaged science students from tier 2 and 3 universities across Karnataka to build careers in life sciences.
• It will support 25 women students, comprising 15 postgraduates (PG) and 10 undergraduates (UG) from life sciences backgrounds, through scholarships, extended internships, and mentorship.
• The initiative will run for 6 months for PG students and 3 months for UG students, providing extensive exposure, training, and mentorship.
• Key program highlights include:
  • Regular Mentor-Mentee Sessions with experts from Biocon Biologics, NCBS, and other institutions.
  • Lab Visits & Scientific Exposure to research labs such as NCBS, TIGS, IISc, and JNC.
  • Bio-Incubation Centre Visits to explore entrepreneurial ecosystems.
  • Hands-on Training & Research Seminars to build technical and scientific thinking skills.
  • Soft Skills & Communication Training for workplace readiness and career planning.
• Biocon Foundation will enable the initiative through funding and expert mentorship from Biocon Biologics, while NCBS will serve as the host institute and academic mentoring partner. BeST Cluster will contribute to the program's design, management, and implementation.
• Dr. Kiran Mazumdar-Shaw, Chairperson, Biocon Group, commented, “At Biocon Group, we believe that science must be inclusive. Empowering women in STEM through our program BioWISE, is not just a moral imperative; it is a strategic investment in our nation’s future. Our commitment to supporting women in science stems from our broader vision of enabling equitable access to health, education, research, and opportunity.”

Biocon Limited announced on June 4, 2025, that its members have approved two key resolutions through a postal ballot conducted via remote e-voting. These resolutions, previously set out in the Postal Ballot Notice dated May 2, 2025, were deemed passed on June 4, 2025, which was the last date for receiving e-votes. The company has submitted the voting results pursuant to Regulation 44(3) of SEBI Listing Regulations and the Scrutinizer’s Report dated June 4, 2025.

• The first resolution, an Ordinary Resolution, concerned the 'Increase in Authorised Share Capital of the Company and consequential amendment to the Memorandum of Association of the Company'.

  • A total of 97,77,69,288 net valid e-votes were polled, representing 81.440% of the total paid-up equity capital as on the cut-off date of April 25, 2025.
  • Out of these, 97,77,59,480 votes (99.999%) were cast in favour of the resolution.
  • Only 9,808 votes (0.001%) were cast against the resolution.

• The second resolution, a Special Resolution, was for 'Raising of funds in one or more tranches, by issuance of Equity Shares and/or other securities'.

  • A total of 97,77,69,418 net valid e-votes were polled, also representing 81.440% of the total paid-up equity capital as on the cut-off date of April 25, 2025.
  • Of the polled votes, 97,28,80,448 votes (99.499%) were in favour of the resolution.
  • 48,88,970 votes (0.500%) were against the resolution.

The company confirmed that both resolutions were approved with the requisite majority. The detailed voting results and the Scrutinizer’s Report are available on Biocon’s official website and the website of its Registrar and Share Transfer Agent (RTA).

Biocon Limited announced on 2 June 2025 that it has received approval in India for its Liraglutide drug substance. Its wholly-owned subsidiary, Biocon Pharma Limited, also received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge) from the Drugs Controller General of India, CDSCO (Central Drugs Standard Control Organisation).

• This approval is for the generic version of Victoza®, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents, and children aged 10 years and above, as an adjunct to diet and exercise.
• The approval was granted under the recently formulated 101 route, which enables recognition of approvals granted by established and referenced serious regulatory authorities.
• Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, stated: “The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon’s mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India.”
• With GLP-1 therapies projected to be a substantive future growth driver for Biocon, the company remains committed to reinforcing its position as a key player in this area.